Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?
Pharmacogenetics is one of the cornerstones of Personalized Precision Medicine that needs to be implemented in the routine of our patients’ clinical management in order to tailor their therapies as much as possible, with the aim of maximizing efficacy and minimizing toxicity. This is of great import...
Main Authors: | Gladys G. Olivera, Andrea Urtasun, Luis Sendra, Salvador F. Aliño, Yania Yáñez, Vanessa Segura, Pablo Gargallo, Pablo Berlanga, Victoria Castel, Adela Cañete, María José Herrero |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/18/9815 |
Similar Items
-
<i>MTHFR</i> and <i>VDR</i> Polymorphisms Improve the Prognostic Value of <i>MYCN</i> Status on Overall Survival in Neuroblastoma Patients
by: Gladys G. Olivera, et al.
Published: (2020-04-01) -
Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy
by: Andrea Urtasun, et al.
Published: (2023-02-01) -
Li-Fraumeni: Will the detection in families increase the survival of its members?
by: Pablo Gargallo, et al.
Published: (2019-01-01) -
Li-Fraumeni: ¿la detección de familias aumentaría la supervivencia entre sus miembros?
by: Pablo Gargallo, et al.
Published: (2019-01-01) -
Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor.
by: Barbara Hämmerle, et al.
Published: (2013-01-01)